| Ivosidenib studied in …STUDIED_INderived46 of 46show fewer |
|---|
| → studied in | NCT03839771Phase 3 · active not recruiting A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia,Myelodysplastic Syndrome/Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07507760Phase 2 · recruiting Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients · 46 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03471260Phase 1/Phase 2 · recruiting Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies · 46 trials list this drug (33 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Myelodysplastic Syndrome,Myeloproliferative Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06291987Phase 1 · recruiting Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation · 46 trials list this drug (33 active) | — | — | Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06717958Phase 2 · recruiting Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation · 46 trials list this drug (33 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04493164Phase 2 · recruiting CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · 46 trials list this drug (33 active) | — | — | Myelodysplastic Syndrome,Myeloproliferative Neoplasm,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07260175Phase 2 · recruiting Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma · 46 trials list this drug (33 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03503409Phase 2 · active not recruiting IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome · 46 trials list this drug (33 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07131059NA · recruiting MRD-positive AML Clinical Study · 46 trials list this drug (33 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06265545NA · recruiting Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07006688Phase 1 · recruiting A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment · 46 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05876754Phase 3 · active not recruiting An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma · 46 trials list this drug (33 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07548710Phase 2 · recruiting Study of SA+X in the Treatment of Newly Diagnosed AML · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155620Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · 46 trials list this drug (33 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07392242Phase 2 · recruiting A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010772Phase 1 · recruiting Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04195555Phase 2 · active not recruiting Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) · 46 trials list this drug (33 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03173248Phase 3 · active not recruiting Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation · 46 trials list this drug (33 active) | — | — | Leukemia,Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05401097Phase 2 · recruiting IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05756777Phase 1 · recruiting A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06707493Phase 2 · recruiting Ivosidenib as Post-HSCT Maintenance for AML · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02074839Phase 1 · recruiting Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation · 46 trials list this drug (33 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04250051Phase 1 · terminated Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia · 46 trials list this drug (33 active) | — | — | Myelodysplastic Syndrome,Myeloproliferative Neoplasm,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07607418Phase 2 · recruiting Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS · 46 trials list this drug (33 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02632708Phase 1 · active not recruiting Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation · 46 trials list this drug (33 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04774393Phase 1/Phase 2 · recruiting Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615818Phase 3 · recruiting Personalized Medicine for Advanced Biliary Cancer Patients · 46 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05907057Phase 3 · recruiting An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04278781Phase 2 · active not recruiting AG-120 in People With IDH1 Mutant Chondrosarcoma · 46 trials list this drug (33 active) | — | — | Chondrosarcoma,Chondrosarcoma, Grade 2,Chondrosarcoma, Grade 3 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02677922Phase 1/Phase 2 · active not recruiting A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy · 46 trials list this drug (33 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02073994Phase 1 · completed Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation · 46 trials list this drug (33 active) | — | — | Chondrosarcoma,Glioma,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03343197Phase 1 · completed Study of AG-120 and AG-881 in Subjects With Low Grade Glioma · 46 trials list this drug (33 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06181734completed Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06127407Phase 3 · recruiting Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen · 46 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07282262Phase 2 · recruiting An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. · 46 trials list this drug (33 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 46 trials list this drug (33 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03564821Phase 1 · completed IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation · 46 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05209074Phase 1 · active not recruiting Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma · 46 trials list this drug (33 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06593548Phase 2 · not yet recruiting Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer · 46 trials list this drug (33 active) | — | — | Malignant Neoplasm,Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02989857Phase 3 · completed Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) · 46 trials list this drug (33 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04955938Phase 1 · withdrawn A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms · 46 trials list this drug (33 active) | — | — | Liquid Tumor,Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04088188Phase 1 · terminated Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma · 46 trials list this drug (33 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04176393Phase 1 · completed A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation · 46 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04655391Phase 1 · withdrawn Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04044209Phase 2 · withdrawn A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS · 46 trials list this drug (33 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03245424approved for marketing Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation · 46 trials list this drug (33 active) | — | — | Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia,Childhood Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |